Immune checkpoint inhibitors are effective in the management of various cancers. However, there are a number of side effects that are linked to the long-term use of these agents, including colitis and myocarditis. Here, Christopher Campen, PharmD, BCOP, from the GHS Cancer Institute, Greenville, SC, discusses the management of the related toxicity and the steps that can be taken to reduce these effects. This video was recorded at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference held in Denver, CO.
Managing the adverse events of immune checkpoint inhibitors
